Global Human Coagulation Factor VIII Market size is valued at USD 8412.3 Million and is forecast to 10040 million the US in 2027, growing at a CAGR of 3.0%.
In the year 1992, Baxter publicized first recombinant factor and it turned out to be popular because it has the same effects as natural coagulation factors but without the risks of blood-borne virus contamination. Master technologies of recombinant coagulation factors has been mastered by developed countries. For instance, recombination coagulation factor VIII has gone through 4 rounds of upgradation. Key players in the market are Pfizer, Bayer and Baxalta among others. There has been no recombinant coagulation factor VIII launched in China in the year 2020. This factor developed quickly after it entered China. Its annual sales volume rose to CNY 481 million in the year 2019 from CNY 6 million in the year 2009 recording a CAGR of 55% during that period. Presently, this factor is all imported from Pfizer, Baxalta and Bayer to be sold in China out of which Bayer has captured 70% of sales in China. It is expected that the market of this factor will continue to grow in China during 2020-to 2024 and there is a possibility that Chinese companies may launch this factor after 2022.
Top Key players in the Human Coagulation Factor VIII Market have been identified through secondary research, and their market shares have been determined through primary and secondary research. The global Human Coagulation Factor VIII Market is fragmented with a large number of small players operating worldwide. The companies referred in the market research report includes Shire (Baxter), Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, BPL, Hualan Bio, RAAS and others.
2014 – Bayer HealthCare today announced positive results from the PROTECT VIII trial evaluating the company’s investigational site-specific PEGylated recombinant human factor VIII compound BAY94-9027. The study met its primary objective of protection from bleeds with fewer infusions. In the study, the site-specific PEGylated factor VIII provided protection from bleeds when used prophylactically every seven days, every five days, and twice per week. The compound was also effective for treatment of acute and breakthrough bleeds with 91 percent of events resolved with one or two infusions.
The market is segmented based on the type, applications, companies and regions.
By Type, Human Coagulation Factor VIII Market has been segmented into
The end user’s industry application on Human Coagulation Factor VIII Market is,
North America is the major consumer of Human Coagulation Factor VIII, accounting for almost 46% of total sales. Human Coagulation Factor VIII has a 58 percent production market share. Human Coagulation Factor VIII is manufactured on a large and medium scale in North America. Europe is in second place, following North America, with a sales market share of 36% and a manufacturing market share of around 28%. Because of the abundant plasma supply in the United States, many European players establish plants there. As a result, there are many Human Coagulation Factor VIIIs available for import from various locations. Asia is another key market for Human Coagulation Factor VIII, with a 10% market share in production and an 11% market share in sales. Factor VIII sales and prices are regulated by country, particularly in China, and the price in China differs from that in other regions.
North America
The Human Coagulation Factor VIII Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Human Coagulation Factor VIII Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
Report Attributes | Report Details |
Report Title | Human Coagulation Factor VIII Market - Global Growth, Trends and Forecast (2022 - 2027) By Types, By Application, By Regions and By Key Players: Shire (Baxter), Bayer, CSL, Pfizer, Grifols |
Forecast Period 2022 to 2028 CAGR | CAGR of 3.0% over the forecast period (2022-2027) |
By Type |
|
By Application |
|
By Companies | Solar Edge, Enphase, Tigo/SMA, APSystems, i-Energy, Lead Solar, Chilicon, BM Solar, Sparq |
Regions Covered |
|
Countries Covered |
|
Base Year | 2022 |
Historical Year | 2017 to 2021 |
Forecast Year | 2022 to 2027 |
Number of Pages | 133 |
Customization Available | Yes, the report can be customized as per your needs |
Frequently Asked Questions
What is the study period of this market?
The Human Coagulation Factor VIII Market is studied from 2017 - 2027.
What is the growth rate of Human Coagulation Factor VIII Market?
The Human Coagulation Factor VIII Market is growing at a CAGR of 3.0% over the next 5 years.
Who are the key players in Human Coagulation Factor VIII Market?
Shire (Baxter), Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, BPL, Hualan Bio, RAAS and others.
What regions does this Human Coagulation Factor VIII Market report covers?
North America (the United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, and Italy)
Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
South America (Brazil, Argentina, Colombia, etc.)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)
What are the significant types of Human Coagulation Factor VIII Market?
Recombinant Factor VIII, Plasma-derived Factor VIII
What are the major end-use applications of the Human Coagulation Factor VIII Market?
Hemophilia A, Spontanous / Trauma, Surgical, Other
All our reports are customizable to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report to your needs.
Application_List
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
Reach us with your research requirements and we shall provide the optimum solution to suit your needs.
Discounts available for multiple report purchases.
